SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

CEO Angelos Stergious next chapter remarks have fueled buyout speculation, while traders are focused on the Phase 3 REGAL AML trials pending 80th-event trigger and eventual results; no acquisition or data leak is confirmed. The rebound has drawn bullish calls, but others view it as volatile, news-free trading and stress that the trial outcome remains uncertain.

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflixs quarterly earnings report is the main focus, with traders watching guidance, subscriber engagement and advertising growth amid a steep share-price decline. Bears point to content concerns, competition and past post-earnings drops, while bulls argue low expectations and a stronger outlook could support a rebound.

IREN Ltd. is a vertically integrated data center business powering the future of Bitcoin, AI and beyond with renewable energy. It is strategically located in renewable-rich, fiber-connected regions across the US and Canada. IREN’s large-scale, grid-connected facilities are purpose-built for the next generation of power-dense computing applications. The company was founded by Daniel Roberts and William Roberts on November 6, 2018, and is headquartered in Sydney, Australia.

IREN Ltd.

IREN Limited

IRENs steep selloff is being discussed amid broader neocloud concerns about financing, AI infrastructure spending returns, and whether providers can remain independent; traders also point to dilution and possible project delays. The community is split between bearish views that the weakness may persist and bullish arguments that IRENs cash-funded data centers and customer prepayments distinguish it from more debt-heavy peers.

General Motors Co. engages in the designing, manufacturing, and selling of trucks, crossovers, cars, and automobile parts, and in providing software-enabled services and subscriptions. It operates through the following segments: GMNA, GMI, Cruise, and GM Financial. The company was founded by William C. Durant on September 16, 1908 and is headquartered in Detroit, MI.

General Motors Company

GM is selling off despite a quarterly earnings beat as investors focus on a narrowed full-year profit outlook with its midpoint unchanged; the new buyback and stronger cash-flow outlook have not offset that concern. Traders are split between buying the dip on capital returns and value, and expecting more downside over cautious guidance and demand pressures.

Space Exploration Technologies Corp., doing business as SpaceX, operates as an aerospace manufacturer, launch service provider, and satellite communications company. It is building the integrated hardware and software infrastructure of the future across space, connectivity, and AI. The firm designs, manufactures, launches, and operates products and services built on cutting-edge technologies, including the rockets and spacecraft. The company was founded by Elon Reeve Musk in 2002 and is headquartered in Starbase, TX.

Space Exploration Technologies Corp. - Ordinary Shares - Class A

SpaceX

SpaceXs Q3 earnings and guidance are dominating discussion, especially whether AI and data-center growth can support heavy capital spending and a return to profitability. Traders are divided between expecting a strong report and worrying that rising spending, financing needs, and an approaching share unlock could weigh on the stock.

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980 and is headquartered in Cambridge, MA.

Sarepta Therapeutics Inc

SRPT is rising alongside a broader biotech rebound, while traders also cite the Silence Therapeutics acquisition as a positive read-through for demand for siRNA therapiesa platform in Sareptas pipeline. The community is split on whether the move reflects sector strength or stock-specific buying, with upcoming DM1 and FSHD data adding to optimism but no new Sarepta catalyst confirmed.

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. It operates through the following geographical segments: United States, Europe, and Rest of World. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rossi, and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Moderna Inc

Traders are focused on the full Phase 3 data for Moderna and Mercks personalized melanoma vaccine at ESMO, following a positive topline result and a sharp rally. Bulls see validation of Modernas cancer-vaccine platform, while skeptics argue expectations and valuation are stretched and warn of a possible sell-the-news reaction.

Sea Ltd. is an internet and mobile platform company, which engages in the provision of online gaming services. It operates through the following segments: Digital Entertainment, E-Commerce, and Digital Financial Services. The Digital Entertainment segment offers and develops mobile and PC online games. The E-Commerce segment manages a third-party marketplace through the Shopee mobile app and websites that connect buyers and sellers. The Digital Financial Services segment includes a variety of payment services and loans to individuals and businesses through SeaMoney. Sea was founded by Xiao Dong Li, Gang Ye, and Jing Ye Chen on May 8, 2009 and is headquartered in Singapore.

Sea Ltd - ADR

Seas steep selloff is being tied to uncertainty over a potential Monee public listing and the planned Sea Cloud venture, with traders concerned about added spending, execution risk and Shopees competition. Some see a Monee listing as value-unlocking and view the decline as a buying opportunity, while others fear it leaves Seas remaining business less attractive.

Alphabet, Inc. is a holding company, which engages in software, health care, transportation, and other technologies. It operates through the following segments: Google Services, Google Cloud, and Other Bets. The Google Services segment includes products and services, such as ads, Android, Chrome, devices, Google Maps, Google Play, Search, and YouTube. The Google Cloud segment refers to infrastructure and platform services, collaboration tools, and other services for enterprise customers. The Other Bets segment relates to the sale of healthcare-related services and internet services. The company was founded by Lawrence E. Page and Sergey Mikhaylovich Brin on October 2, 2015 and is headquartered in Mountain View, CA.

Alphabet Inc - Ordinary Shares - Class A

Alphabet Inc Class A

Alphabets weak price action and difficulty sustaining rebounds dominate discussion, with traders linking pressure to the broader tech and AI selloff and weighing cloud growth against heavy AI spending and cash-flow concerns ahead of earnings. Bulls see the pullback as a buying opportunity, while bears point to technical weakness and capex risks.

Intuitive Surgical, Inc. engages in the provision of robotic-assisted surgical solutions and invasive care through a comprehensive ecosystem of products and services. Its products include Da Vinci Surgical and Ion Endoluminal systems. The company was founded by Frederic H. Moll, John Gordon Freund, and Robert G. Younge in November 1995 and is headquartered in Sunnyvale, CA.

Intuitive Surgical Inc

Intuitive Surgical is drawing attention after a sharp post-earnings selloff despite beating expectations, as investors focused on slower U.S. da Vinci procedure growth and a cautious outlook. Traders are split between viewing the decline as an overreaction given the companys robotic-surgery position and recurring revenue, and seeing valuation, competition, and growth uncertainty as reasons for a reset.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Bicycle Therapeutics Reports Recent Business Progress and Second Quarter 2026 Financial Results

Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle) technology, today reported financial results for the second quarter ended June 30, 2026, and provided recent corporate...

Tarsus Pharmaceuticals (TARS) Moves 7.5% Higher: Will This Strength Last?

Tarsus Pharmaceuticals (TARS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Bicycle Therapeutics to Present Initial Duravelo-2 Data at 2026 ASCO Annual Meeting

Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle) technology, today announced the presentation of initial data from the randomized Phase 2 trial (Duravelo-2) evaluating...

Bicycle Therapeutics (NASDAQ:BCYC) Rating Lowered to "Sell" at Wall Street Zen

Wall Street Zen cut shares of Bicycle Therapeutics from a 'hold' rating to a 'sell' rating in a research report on Saturday...

Bicycle Therapeutics (NASDAQ:BCYC) Announces Earnings Results, Misses Estimates By $0.25 EPS

Bicycle Therapeutics (NASDAQ:BCYC - Get Free Report) released its quarterly earnings results on Thursday. The company reported ($0.87) earnings per share (EPS) for the quarter, missing analysts...

Bicycle Therapeutics Reports Recent Business Progress and First Quarter 2026 Financial Results

Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle) technology, today...

Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) Given Consensus Recommendation of "Moderate Buy" by Brokerages

Shares of Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC - Get Free Report) have been assigned a consensus recommendation of "Moderate Buy" from the eleven brokerages that are presently covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell re...

Bicycle Therapeutics (BCYC) to Release Quarterly Earnings on Thursday

Bicycle Therapeutics (NASDAQ:BCYC) will be releasing its Q1 2026 earnings before the market opens on Thursday, April 30. (View Earnings Report at...

Bicycle Therapeutics Announces Oral and Poster Presentations at the 2026 ASCO Annual Meeting

Bicycle Therapeutics Provides Update on Nuzefatide Pevedotin and EphA2 Pipeline at the AACR Annual Meeting 2026

Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle) technology, today announced updates from its EphA2 pipeline at the American Association for Cancer Research (AACR) Annual...

Bicycle Therapeutics Plc is a clinical-stage biopharmaceutical company, which engages in the development of a novel class of medicines, which the company refers to as bicycles, for diseases that are underserved by existing therapeutics. Its portfolio includes internal product candidates that are directed to oncology applications. The company was founded by Gregory Winter, John Tite, and Christian Heinis in 2009 and is headquartered in Cambridge, the United Kingdom.

Bicycle Therapeutics Plc - ADR

Neutral Sentiment

Double beat (rev + EPS)

Revenue beat, EPS miss

EPS beat, revenue miss

Double miss

SpaceX ($SPCX) reports earnings after the close today. What do you expect?

Stocktwits

) reports earnings after the close today. What do you expect?

Current Price	$3.60
Prev Close	$3.54
Open	$3.52
Dividend Yield	0.00%
50-Day Moving Average	$3.90
Beta	1.24
Avg. Volume	441,390.22
PE Ratio	-1.29

52-Week High	$9.08
52-Week Low	$3.33
Market Capitalization	$178.08M
EPS (Annual)	-$3.17
Price to Book	0.48
Revenue Per Employee	$252,623.69

Feed

News

Sentiment

Earnings

Fundamentals

Info

BCYC Fundamentals